A recent report published by Infinium Global Research on hepatorenal syndrome treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional hepatorenal syndrome treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hepatorenal syndrome treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global hepatorenal syndrome treatment market. According to the report, the global hepatorenal syndrome treatment market is projected to grow at a CAGR of 4.8% over the forecast period of 2019-2025.

Market Insight

Hepatorenal syndrome is a functional and reversible form of renal failure in patients with advanced chronic liver diseases. It is the most severe complication of cirrhosis. Hepatorenal syndrome is almost always fatal. Hepatorenal syndrome patients commonly have a variety of symptoms such as weakness, abdominal pain, and discomfort. To prevent Hepatorenal syndrome, several therapeutics and surgical treatments are available in the market.

The growing awareness regarding Hepatorenal syndrome diagnosis and treatment thereby stimulating the growth of the global market for the treatment of Hepatorenal syndrome. Additionally, growing incidences of hepatorenal syndrome are also boosting the growth of the market. It is estimated that near about 40% of patients with stage 4 or 5 of chronic kidney disease receive simultaneous liver-kidney transplants (SLKs), according to the Clinical Journal of American Society of Nephrology (CJASN) 2017. Moreover, increasing support from the government regarding campaigns program to improve hepatorenal syndrome care is likely to enhance the growth of the market. Further, Nowadays, Pharmaceuticals companies operating in this market are developing therapeutic drugs that are safe and effective for Hepatorenal syndrome patients. For instance, In August 2019, Mallinckrodt plc, a global biopharmaceutical company, announced the launch of terlipressin for the treatment of hepatorenal syndrome type 1 (HRS-1). Furthermore, increasing research and development by the companies to reduce economies burden on patients, and the availability of advanced treatment options at U.S. hospitals augment the demand of the market. For instance, it is estimated that the cost of treatment for HRS is less expensive in India as compared to the developed countries. However, the high cost of treatment is expected to hamper the growth of the global hepatorenal syndrome treatment market over the forecast period. Moreover, the launch of various pipeline drugs for the treatment of hepatorenal syndrome in the coming years creates growth opportunities for the market

Among the geographies, the global hepatorenal syndrome treatment market is bifurcated into North America, Europe, Asia Pacific, and Row. North America dominates the global hepatorenal syndrome treatment market. Moreover, an estimated 12,000 to 33,000 Americans develop HRS each year. The factors such as increasing incidences of HRS, well-developed healthcare infrastructures and the launch of new pipeline drugs in this region propelling the growth of North America hepatorenal syndrome treatment market. Favorable reimbursement policies for chronic kidney disease patients are likely to have a positive impact on regional growth. Further, the U.S. is accounted for the largest revenues in this market. On the other hand, developing countries of Asia Pacific hold great opportunities for the hepatorenal syndrome treatment market due to their growth in population coupled with growing healthcare expenditure.

Segment Covered

The report on the global hepatorenal syndrome treatment market covers segments such as type, treatment, and end user. On the basis of type, the sub-markets include type 1 hepatorenal syndrome, and type 2 hepatorenal syndrome. On the basis of treatment, the sub-markets include therapeutics, and surgical treatment. On the basis of end user, the sub-markets include hospitals & clinics, ambulatory surgical centers, academic & research institutes, and other end-users.

Companies Profiled:

The report provides profiles of the companies in the market such as Mallinckrodt Pharmaceuticals, BioVie, Cumberland Pharmaceuticals Inc, Orphan Therapeutics, LLC, and Other Companies.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the hepatorenal syndrome treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.